Buprenorphine and Verapamil: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Verapamil
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Verapamil can make buprenorphine stronger than intended. Verapamil (a blood pressure and heart medicine) slows down a liver enzyme called CYP3A4 that normally breaks down buprenorphine. When that enzyme is blocked, more buprenorphine stays in your body. This can lead to stronger and longer opioid effects, like feeling very sleepy or, in more serious cases, slowed or shallow breathing.
The good news is that your care team can manage this well. They may adjust your buprenorphine dose and watch you a bit more closely, especially when you first start or stop verapamil. Please don't change either medicine on your own, just talk with your pharmacist or doctor so they can keep you safe.
Mechanism: Verapamil is a moderate CYP3A4 inhibitor; buprenorphine is a CYP3A4 substrate (active drug, not a prodrug). Inhibition reduces buprenorphine metabolism, increasing plasma exposure.
Direction/effect: Increased buprenorphine AUC/Cmax, raising risk of prolonged opioid effects including sedation and respiratory depression. Severity major; evidence probable; onset unspecified.
Management:
- If starting verapamil, consider reducing buprenorphine dose until stable; monitor frequently for sedation/respiratory depression.
- On verapamil discontinuation, consider increasing buprenorphine dose and monitor for withdrawal.
- For fixed-dose formulations (subQ depot), use one permitting precise titration if adjustment is needed.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Because buprenorphine plasma concentrations rise when it is combined with a CYP3A4 inhibitor, extended opioid effects such as respiratory depression can result. When a patient on buprenorphine must also receive a CYP3A4 inhibitor, one option is to lower the buprenorphine dose until drug effects stabilize, along with frequent monitoring for sedation and respiratory depression. Conversely, stopping a CYP3A4 inhibitor in a patient who is on buprenorphine may warrant raising the buprenorphine dose until stable drug effects are reached, with monitoring for opioid withdrawal signs2. If dose adjustment is not feasible once the CYP3A4 inhibitor is no longer present, switch the patient back to a buprenorphine formulation that allows finer dose titration. For patients being converted from transmucosal buprenorphine taken together with CYP3A4 inhibitors, verify that the plasma buprenorphine concentration achieved with subQ buprenorphine is sufficient. For those already receiving subQ buprenorphine who need a CYP3A4 inhibitor, watch for indications of over-medication. Should signs and symptoms of buprenorphine toxicity or overdose develop while the co-administered medication cannot be lowered or stopped, decrease the buprenorphine dose. If the available doses do not allow the intended dose to be reached, stop treatment and manage the patient with a buprenorphine formulation that permits more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring.
Here is what your team typically does:
- They may lower your buprenorphine dose when verapamil is added, and watch closely for extra drowsiness or slowed breathing.
- When verapamil is stopped, they may raise the buprenorphine dose back up and watch for signs of opioid withdrawal.
- If you use a long-acting injectable form, they may switch you to a form that allows more precise dose adjustments.
Tell your pharmacist or doctor right away if you notice unusual sleepiness, confusion, or slow/shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, such interactions have been demonstrated in studies employing transmucosal buprenorphine. Buprenorphine's effects may vary according to the route by which it is administered 1.
Common questions
Can I take Buprenorphine and Verapamil together?
Verapamil can raise buprenorphine levels and increase the risk of excess sedation and slowed breathing, so your care team may adjust your buprenorphine dose and monitor you more closely. Do not change either medication on your own; contact your pharmacist or doctor with any concerns. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Verapamil interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Verapamil interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring. Here is what your team typically does: They may lower your buprenorphine dose when verapamil is added, and watch closely for extra drowsiness or slowed breathing. When verapamil is stopped, they may raise the buprenorphine dose back up and wa… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Buprenorphine or Verapamil need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Verapamil
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist